Free Trial

Fulcrum Therapeutics (FULC) News Today

Fulcrum Therapeutics logo
$2.99 -0.02 (-0.66%)
(As of 11/20/2024 ET)
Fulcrum Therapeutics, Inc. stock logo
Fulcrum Therapeutics, Inc. (NASDAQ:FULC) Receives Consensus Rating of "Hold" from Brokerages
Fulcrum Therapeutics, Inc. (NASDAQ:FULC - Get Free Report) has received an average rating of "Hold" from the ten research firms that are currently covering the firm, MarketBeat Ratings reports. One investment analyst has rated the stock with a sell rating, six have issued a hold rating and three
HC Wainwright Has Positive Outlook for FULC FY2024 Earnings
Fulcrum Therapeutics, Inc. stock logo
Research Analysts Issue Forecasts for FULC FY2024 Earnings
Fulcrum Therapeutics, Inc. (NASDAQ:FULC - Free Report) - Stock analysts at HC Wainwright raised their FY2024 EPS estimates for Fulcrum Therapeutics in a research report issued to clients and investors on Thursday, November 14th. HC Wainwright analyst A. Fein now expects that the company will post
Fulcrum Therapeutics, Inc. stock logo
Simplify Asset Management Inc. Sells 323,518 Shares of Fulcrum Therapeutics, Inc. (NASDAQ:FULC)
Simplify Asset Management Inc. reduced its position in Fulcrum Therapeutics, Inc. (NASDAQ:FULC - Free Report) by 47.9% during the third quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 351,314 shares of the company's stock after selling 323,518 shares
Fulcrum Therapeutics, Inc. stock logo
Fulcrum Therapeutics' (FULC) "Neutral" Rating Reiterated at HC Wainwright
HC Wainwright reiterated a "neutral" rating and set a $4.00 price target on shares of Fulcrum Therapeutics in a research report on Thursday.
Fulcrum Therapeutics expects cash to fund operations into at least 2027
Fulcrum Therapeutics Reports Q3 2024 Financial Progress
Fulcrum Therapeutics, Inc. stock logo
Fulcrum Therapeutics (FULC) Scheduled to Post Earnings on Wednesday
Fulcrum Therapeutics (NASDAQ:FULC) will be releasing earnings before the market opens on Wednesday, November 13, Zacks reports.
Fulcrum Therapeutics, Inc. stock logo
Assenagon Asset Management S.A. Has $1.22 Million Position in Fulcrum Therapeutics, Inc. (NASDAQ:FULC)
Assenagon Asset Management S.A. reduced its stake in Fulcrum Therapeutics, Inc. (NASDAQ:FULC - Free Report) by 31.6% during the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 340,495 shares of the company's stock
Fulcrum Therapeutics, Inc. stock logo
Short Interest in Fulcrum Therapeutics, Inc. (NASDAQ:FULC) Decreases By 6.4%
Fulcrum Therapeutics, Inc. (NASDAQ:FULC - Get Free Report) was the target of a large decline in short interest in October. As of October 15th, there was short interest totalling 5,520,000 shares, a decline of 6.4% from the September 30th total of 5,900,000 shares. Based on an average daily volume of 1,650,000 shares, the days-to-cover ratio is currently 3.3 days.
Fulcrum Therapeutics, Inc. stock logo
Fulcrum Therapeutics, Inc. (NASDAQ:FULC) Receives Consensus Rating of "Hold" from Analysts
Shares of Fulcrum Therapeutics, Inc. (NASDAQ:FULC - Get Free Report) have received a consensus recommendation of "Hold" from the ten brokerages that are currently covering the stock, MarketBeat.com reports. One research analyst has rated the stock with a sell rating, six have assigned a hold rati
Fulcrum Therapeutics, Inc. stock logo
Fulcrum Therapeutics Sees Unusually High Options Volume (NASDAQ:FULC)
Fulcrum Therapeutics, Inc. (NASDAQ:FULC - Get Free Report) saw unusually large options trading on Wednesday. Stock investors purchased 30,075 call options on the company. This represents an increase of approximately 1,522% compared to the typical volume of 1,854 call options.
Fulcrum Therapeutics, Inc. stock logo
Dimensional Fund Advisors LP Has $9.18 Million Position in Fulcrum Therapeutics, Inc. (NASDAQ:FULC)
Dimensional Fund Advisors LP increased its holdings in shares of Fulcrum Therapeutics, Inc. (NASDAQ:FULC - Free Report) by 13.5% during the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 1,480,926 shares of the company's stock aft
Fulcrum Therapeutics, Inc. stock logo
Fulcrum Therapeutics, Inc. (NASDAQ:FULC) Given Consensus Recommendation of "Hold" by Analysts
Fulcrum Therapeutics, Inc. (NASDAQ:FULC - Get Free Report) has earned an average rating of "Hold" from the ten research firms that are covering the stock, Marketbeat.com reports. One research analyst has rated the stock with a sell rating, six have issued a hold rating and three have given a buy
Fulcrum Therapeutics, Inc. stock logo
Fulcrum Therapeutics, Inc. (NASDAQ:FULC) Sees Significant Growth in Short Interest
Fulcrum Therapeutics, Inc. (NASDAQ:FULC - Get Free Report) was the target of a large growth in short interest during the month of September. As of September 15th, there was short interest totalling 11,400,000 shares, a growth of 41.4% from the August 31st total of 8,060,000 shares. Based on an average trading volume of 1,680,000 shares, the days-to-cover ratio is presently 6.8 days.
Fulcrum Therapeutics, Inc. stock logo
186,727 Shares in Fulcrum Therapeutics, Inc. (NASDAQ:FULC) Bought by Bank of New York Mellon Corp
Bank of New York Mellon Corp bought a new stake in Fulcrum Therapeutics, Inc. (NASDAQ:FULC - Free Report) during the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor bought 186,727 shares of the compa
Fulcrum Therapeutics, Inc. stock logo
Brokers Issue Forecasts for Fulcrum Therapeutics, Inc.'s FY2024 Earnings (NASDAQ:FULC)
Fulcrum Therapeutics, Inc. (NASDAQ:FULC - Free Report) - Stock analysts at Leerink Partnrs lifted their FY2024 earnings estimates for Fulcrum Therapeutics in a research report issued to clients and investors on Thursday, September 12th. Leerink Partnrs analyst J. Schwartz now anticipates that the
Stifel Downgrades Fulcrum Therapeutics (FULC)
Fulcrum Therapeutics, Inc. stock logo
Fulcrum Therapeutics (NASDAQ:FULC) Downgraded to Neutral at HC Wainwright
HC Wainwright lowered Fulcrum Therapeutics from a "buy" rating to a "neutral" rating and decreased their target price for the company from $17.00 to $4.00 in a research report on Friday.
Fulcrum Therapeutics, Inc. stock logo
Fulcrum Therapeutics (NASDAQ:FULC) Downgraded by Royal Bank of Canada to Sector Perform
Royal Bank of Canada cut Fulcrum Therapeutics from an "outperform" rating to a "sector perform" rating and dropped their price objective for the stock from $15.00 to $4.00 in a report on Thursday.
Get Fulcrum Therapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for FULC and its competitors with MarketBeat's FREE daily newsletter.

Breaking News: Tesla headed to $500… (Ad)

That headline hit late last night…and the rally has begun Which is why we want to urge you to go ahead and download Lance’s e-Book now outlining his bullish case for Tesla.

So to claim your free digital copy today, simply follow this link and enter your email address. 

FULC Media Mentions By Week

FULC Media Sentiment

Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press.

FULC
News Sentiment

0.70

0.45

Average
Medical
News Sentiment

FULC News Coverage

We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week.

FULC Articles
This Week

16

4

FULC Articles
Average Week

Get Fulcrum Therapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for FULC and its competitors with MarketBeat's FREE daily newsletter.


Related Companies and Tools


This page (NASDAQ:FULC) was last updated on 11/21/2024 by MarketBeat.com Staff
From Our Partners